The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-More foreign pharmaceutical firms could be probed in China-Xinhua

Wed, 24th Jul 2013 12:41

By Michael Martina

BEIJING, July 24 (Reuters) - China's official news agencyhinted that more foreign pharmaceutical firms could soon beimplicated in a corruption scandal sweeping the industry, in thewake of bribery accusations against British drugmakerGlaxoSmithKline.

"It will not be surprising if more pharmaceutical companiesand hospitals, domestic or international, are to be involved inprobes in the days to come," the Xinhua news agency said onWednesday in an English-language commentary.

Xinhua did not name any firms or hospitals, but said thegovernment was trying to tackle "rampant" malpractice in thepharmaceutical sector, including corruption.

Underscoring the rot in China's health sector, state mediasaid more than 1,000 doctors, nurses and administrators at 73hospitals in Zhangzhou city in the southeastern province ofFujian had been found taking kickbacks.

State broadcaster CCTV said 90 percent of the city's doctorswere involved and that authorities had recovered 20.5 millionyuan ($3.34 million) in illicit funds after a six monthinvestigation.

A lot of the kickbacks revolved around the distribution ofmedicines, CCTV said. It said 57 people, called "drug reps" inthe report, had been detained. CCTV did not name any companies.

Chinese police have accused GlaxoSmithKline of funnelling upto 3 billion yuan ($488.81 million) to travel agencies tofacilitate bribes to doctors and officials to boost sales andthe price of its medicines in China.

GSK has called the accusations "shameful" and on Monday saidsome of its Chinese executives appeared to have broken the law.

Xinhua said multinational pharmaceutical companies shouldset a good example for local firms.

"Big international firms should shoulder (their) dueresponsibilities to bid farewell to malpractice," it said.

Such commentaries, while not official statements, provide awindow into the government's thinking. English-languagecommentaries are also often intended for internationalconsumption.

GOVERNMENT CRACKDOWN

Xinhua said the following government agencies were alltaking action: the ministries of public security and health, theNational Development and Reform Commission, which sets prices,and the State Administration for Industry and Commerce, aregulator.

"It is true that malpractice has (been) rampant in China'spharmaceutical industry and hospitals for years, but now China(is) determined to reform its health system and root outmalpractice, including taking kickbacks and price-fixing," thecommentary added.

Chinese police have questioned local employees from anotherBritish drugmaker, AstraZeneca. The company has saidpolice were treating this as an individual case and not relatedto other investigations.

Authorities have also visited the offices of Belgiandrugmaker UCB.

And the authorities have detained a British and a U.S.citizen, although it is not clear if those detentions weredirectly linked to the pharmaceutical probe sparked by the GSKallegations.

Corruption in China's pharmaceutical industry is fuelled inpart by the low base salaries for doctors at the country's13,500 public hospitals.

On Tuesday, Xinhua said 39 employees at a hospital insouthern Guangdong province would be punished for takingkickbacks totalling 2.82 million yuan from two local drugmakersbetween January 2010 and December 2012.

China has committed to making health care affordable for its1.37 billion people.

But ordinary Chinese cite the cost of medicine as a majorirritant. Many Chinese prefer foreign brands over local drugsbecause of the widespread circulation of fake medicine.

China's State Council, or cabinet, on Wednesday said in astatement posted on the government's website that it wouldreform drug pricing and procurement mechanisms, guarantee drugquality and "fairly reduce drug costs ... and resolutelyinvestigate illicit kickback behaviour".

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.